An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable, Progressive/Symptomatic Plexiform Neurofibromas (PN)
Latest Information Update: 05 May 2020
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Expanded access; Therapeutic Use
- Sponsors AstraZeneca
- 30 Apr 2020 Status changed from recruiting to completed.
- 28 Aug 2017 New trial record